High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.

M Mohty, D Blaise, C Faucher, V-J Bardou, J-A Gastaut, P Viens, D Olive, B Gaugler, Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia. ,vol. 19, pp. 1- 6 ,(2005) , 10.1038/SJ.LEU.2403558

PAUL R. ROSENBAUM, DONALD B. RUBIN, The central role of the propensity score in observational studies for causal effects Biometrika. ,vol. 70, pp. 41- 55 ,(1983) , 10.1093/BIOMET/70.1.41

Ayalew Tefferi, Animesh Pardanani, Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis Mayo Clinic Proceedings. ,vol. 86, pp. 1188- 1191 ,(2011) , 10.4065/MCP.2011.0518

Giacomo Coltro, Francesco Mannelli, Paola Guglielmelli, Annalisa Pacilli, Alberto Bosi, Alessandro Maria Vannucchi, A life-threatening ruxolitinib discontinuation syndrome. American Journal of Hematology. ,vol. 92, pp. 833- 838 ,(2017) , 10.1002/AJH.24775

Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, Francesco Passamonti, Richard T. Silver, Ronald Hoffman, Srdan Verstovsek, Ruben Mesa, Jean-Jacques Kiladjian, Rȕdiger Hehlmann, Andreas Reiter, Francisco Cervantes, Claire Harrison, Mary Frances Mc Mullin, Hans Carl Hasselbalch, Steffen Koschmieder, Monia Marchetti, Andrea Bacigalupo, Guido Finazzi, Nicolaus Kroeger, Martin Griesshammer, Gunnar Birgegard, Giovanni Barosi, Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet Leukemia. ,vol. 32, pp. 1057- 1069 ,(2018) , 10.1038/S41375-018-0077-1

Graziano Onder, Giovanni Rezza, Silvio Brusaferro, None, Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. ,vol. 323, pp. 1775- 1776 ,(2020) , 10.1001/JAMA.2020.4683

Safiya Richardson, Jamie S. Hirsch, Mangala Narasimhan, James M. Crawford, Thomas McGinn, Karina W. Davidson, Douglas P. Barnaby, Lance B. Becker, John D. Chelico, Stuart L. Cohen, Jennifer Cookingham, Kevin Coppa, Michael A. Diefenbach, Andrew J. Dominello, Joan Duer-Hefele, Louise Falzon, Jordan Gitlin, Negin Hajizadeh, Tiffany G. Harvin, David A. Hirschwerk, Eun Ji Kim, Zachary M. Kozel, Lyndonna M. Marrast, Jazmin N. Mogavero, Gabrielle A. Osorio, Michael Qiu, Theodoros P. Zanos, , Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. ,vol. 323, pp. 2052- 2059 ,(2020) , 10.1001/JAMA.2020.6775

Naveen Pemmaraju, Jingbo Yu, Shreekant Parasuraman, Dilan Paranagama, Jonathan Kish, Jay Visaria, Mukul Singhal, Srdan Verstovsek, Aaron Thomas Gerds, None, Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes. Journal of Clinical Oncology. ,vol. 38, ,(2020) , 10.1200/JCO.2020.38.15_SUPPL.E19535

F. La Rosée, H. C. Bremer, I. Gehrke, A. Kehr, A. Hochhaus, S. Birndt, M. Fellhauer, M. Henkes, B. Kumle, S. G. Russo, P. La Rosée, The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. ,vol. 34, pp. 1805- 1815 ,(2020) , 10.1038/S41375-020-0891-0

Luca Carsana, Aurelio Sonzogni, Ahmed Nasr, Roberta Simona Rossi, Alessandro Pellegrinelli, Pietro Zerbi, Roberto Rech, Riccardo Colombo, Spinello Antinori, Mario Corbellino, Massimo Galli, Emanuele Catena, Antonella Tosoni, Andrea Gianatti, Manuela Nebuloni, Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infectious Diseases. ,vol. 20, pp. 1135- 1140 ,(2020) , 10.1016/S1473-3099(20)30434-5